Apogee Therapeutics (APGE) Cash & Current Investments (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash & Current Investments data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 106.48% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 106.48% increase from a year earlier, with the FY2025 full-year figure at $730.2 million, up 40.25% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $1.1 billion, up from $730.2 million in the prior quarter.
• Over the last five years, Cash & Current Investments for APGE reached as high as $1.1 billion in Q1 2026 and fell as low as $5.0 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $498.2 million across 5 years, with a median of $517.0 million in 2024.
• Across the five-year window, Cash & Current Investments surged 2414.46% in 2023 and tumbled 37.11% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $151.9 million in 2022, then jumped by 160.36% to $395.5 million in 2023, then surged by 31.66% to $520.7 million in 2024, then soared by 40.25% to $730.2 million in 2025, then surged by 45.15% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $1.1 billion in Q1 2026, $730.2 million in Q4 2025, and $527.3 million in Q3 2025.